#PRV131
LightNews LightNews
newsen.bsky.social
Privo Technologies Commences First Human Dosing of PRV131 in Pioneering Oral Cancer Treatment Trial#USA#Boston#Privo_Technologies#Oral_Cancer#PRV131
Privo Technologies Commences First Human Dosing of PRV131 in Pioneering Oral Cancer Treatment Trial
Privo Technologies has officially begun dosing its first patient in a groundbreaking clinical trial for PRV131, an innovative injectable for oral cavity cancer, showcasing phase 1/2 advancements.
third-news.com
December 10, 2025 at 8:19 PM
l2plabs.bsky.social
Privo Technologies Begins Dosing PRV131 in Arm 3 Of Clinical Study CLN-004, A First-In-Class Cisplatin Intratumoral Injectable Targeting Oral Cavity Cancer
Key Highlights: First-in-human milestone: The inaugural patient has been dosed with PRV131. Precise, localized delivery: Built on Privo's PRV Platform technology, PRV131 delivers high concentrations of cisplatin directly to tumors, while minimizing systemic exposure. BOSTON, Mass., Dec....
dlvr.it
December 10, 2025 at 8:10 PM